X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers.
Lead Product(s): TCR-T Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Anocca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2024
Details:
EmendoBio to operate as an independent subsidiary of AnGes with full access to AnGes’ global development resources to accelerate development and manufacturing capabilities for EmendoBio’s dual OMNI™ genome editing technology platforms.
Lead Product(s): EMD-101
Therapeutic Area: Genetic Disease Product Name: EMD-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AnGes
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 15, 2020
Details:
The funding will accelerate novel OMNI gene editing platform into a broad therapeutic product pipeline.
Lead Product(s): OMNI nuclease
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AnGes
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
